Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.





Grünenthal appoints Dr. Jan Adams as Chief Commercial Officer (FOTO)

30.09.2024, 2231 Zeichen

Aachen, Germany (OTE) - Grünenthal announced today that Jan Adams, M.D., currently Chief Scientific Officer (CSO) and member of the Corporate Executive Board, will assume the role of Chief Commercial Officer (CCO) effective 1 October 2024. Prior to his role as CSO, he was Head of Strategy and Portfolio at Grünenthal.
Jan Adams has over two decades of experience in the pharmaceutical and healthcare industry. Since joining Grünenthal in 2017, he has been key in driving the company's transformational journey. Under his leadership, Grünenthal successfully built a state- of-the-art R&D organisation, redefined its R&D strategy, and built an industry-leading pipeline focused on delivering innovative treatments for acute and chronic pain. Before assuming the role of CSO, he served as Head of Strategy and Portfolio, working at the interface between Strategy, R&D, and Commercial. His role was instrumental in several successful M&A projects and Grünenthal’s entry into the U.S. market. Before joining Grünenthal, he held positions with increasing responsibilities at Takeda, McKinsey & Company, and Novartis. Jan Adams started his career as a resident in cardiology. He is a Medical Doctor by training, married, and has two children.
Jan Adams succeeds Janneke van der Kamp, who will leave Grünenthal to pursue an opportunity outside the company.
About Grünenthal
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better - and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2023, Grünenthal employed around 4,400 people and achieved revenues of Ꞓ1.8 billion.
More information: https://www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group
Instagram: grunenthal
Digital press kit: http://www.ots.at/pressemappe/DE118252/aom



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #772: ATX etwas stärker in den November, Oktober war Na Prack, Oida mit schweren Verlusten in der 2. Reihe


 

Aktien auf dem Radar:Agrana, Pierer Mobility, Warimpex, Immofinanz, CA Immo, Flughafen Wien, voestalpine, Verbund, AT&S, EVN, Lenzing, ATX, ATX Prime, ATX TR, Wienerberger, Wolford, Frequentis, Andritz, DO&CO, Strabag, Erste Group, Marinomed Biotech, RBI, Telekom Austria, Oberbank AG Stamm, Zumtobel, Palfinger, Amag, Österreichische Post, S Immo, Uniqa.


Random Partner

Montana Aerospace
Montana Aerospace zählt dank ihrer globalen Präsenz in Entwicklung und Fertigung sowie ihrer Multimaterial-Kompetenz zu den weltweit führenden Herstellern von komplexen Leichtbaukomponenten und Strukturen für die Luftfahrtindustrie. Als hochgradig integrierter Komplettanbieter mit State-of-the-Art-Fertigungsstätten in Europa, Amerika und Asien unterstützen wir die Local-to-Local-Strategie unserer Kunden.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Mehr aktuelle OTS-Meldungen HIER